logo

NUPLAZID™ (pimavanserin) tablets

Please see package insert for additional information and possible updates. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.    [  Read the disclaimer    |   <<Back      |  Other antipsychotics led    ]
CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION HOW SUPPLIED

CLINICAL PHARMACOLOGY: top of page

BOXED WARNING:
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis

Initial U.S. Approval:  2016


Mechanism of Action:
The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with Parkinson's disease psychosis is unknown. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.

INDICATIONS AND USAGE  top of page

INDICATIONS AND USAGE:
NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

DOSAGE AND ADMINISTRATION  top of page

Drug UPDATES:  NUPLAZID™ (pimavanserin) tablets
[Drug information  /  PDF]  
Package insert - Dosing:  Click (+) next to Dosage and Administration section (drug info link)

DOSAGE AND ADMINISTRATION
Recommended dose is 34 mg, taken orally as two 17 mg tablets once daily, without titration.
Can be taken with or without food.

HOW SUPPLIED top of page

HOW SUPPLIED:
Tablets: 17 mg.

REFERENCE

Drug UPDATES:  NUPLAZID™ (pimavanserin) tablets
[Drug information  /  PDF]  
Package insert
Medical Calculators - A thru Z
Lab Values - A thru Z